- Home
- CRIS vs KALA Comparison
CRIS vs KALA Comparison
Compare CRIS & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- KALA
- Stock Information
- Founded
- CRIS 2000
- KALA 2009
- Country
- CRIS United States
- KALA United States
- Employees
- CRIS N/A
- KALA N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- KALA Health Care
- Exchange
- CRIS Nasdaq
- KALA Nasdaq
- Market Cap
- CRIS 22.9M
- KALA 26.2M
- IPO Year
- CRIS 2000
- KALA 2017
- Fundamental
- Price
- CRIS $1.77
- KALA $18.02
- Analyst Decision
- CRIS Strong Buy
- KALA Strong Buy
- Analyst Count
- CRIS 2
- KALA 3
- Target Price
- CRIS $16.50
- KALA $25.00
- AVG Volume (30 Days)
- CRIS 75.9K
- KALA 266.2K
- Earning Date
- CRIS 11-13-2025
- KALA 11-11-2025
- Dividend Yield
- CRIS N/A
- KALA N/A
- EPS Growth
- CRIS N/A
- KALA N/A
- EPS
- CRIS N/A
- KALA N/A
- Revenue
- CRIS $11,405,000.00
- KALA N/A
- Revenue This Year
- CRIS $1.41
- KALA N/A
- Revenue Next Year
- CRIS $7.46
- KALA N/A
- P/E Ratio
- CRIS N/A
- KALA N/A
- Revenue Growth
- CRIS 12.24
- KALA N/A
- 52 Week Low
- CRIS $1.02
- KALA $2.92
- 52 Week High
- CRIS $6.44
- KALA $18.89
- Technical
- Relative Strength Index (RSI)
- CRIS 52.53
- KALA 84.77
- Support Level
- CRIS $1.63
- KALA $13.14
- Resistance Level
- CRIS $1.95
- KALA $15.66
- Average True Range (ATR)
- CRIS 0.14
- KALA 1.59
- MACD
- CRIS 0.02
- KALA 0.59
- Stochastic Oscillator
- CRIS 45.59
- KALA 88.86
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.